Change in leadership at Curidium Medica

Gosse B. Bruinsma is moving from the position of chairman to the non-executive director of personalised medicine company Curidium Medica.

In addition, Dr Barry Porter, co-founder and currently non-executive director becomes chairman.

Bruinsma has cited his other business obligations and Curidium's need for dedicated leadership at this important time as reasons for the strategic change.

Led by Porter, Curidium has initiated a strategic review to maximise its commercial development opportunities. With the pharmaceutical industry's growing interest in personalised medicine the company will ensure its intellectual property assets and strong balance sheet are fully utilised to deliver optimum value to shareholders.

Curidium will enhance its r&d activities, with the aim of fully leveraging its product portfolio in support of business development activities as the company continues to receive positive feedback from customers on PsychINDx - a diagnostic blood test that classifies patients with schizophrenia/bipolar disorder into different subgroups, which may result in the improved treatment of these patients.

Porter, said: "On behalf of the Board, I would like to thank Gosse for his contribution and achievements during his time as chairman. This is a very exciting time for Curidium; the regulators and leading drug companies are beginning to recognise the significant importance of personalised medicines and I believe the company is well placed to capitalise on this in the near future."